In the following video, Motley Fool health-care analyst David Williamson explains what's behind a massively important trial for Vertex Pharmaceuticals (NASDAQ:VRTX). The company's cystic fibrosis drug Kalydeco currently treats only about 4% of the population, but Vertex is looking to apply the drug to a more common mutation of the disease, which would expand the drug's reach to be effective for nearly half of the CF patient population. David tells investors just how much money is at stake in this market, and what's at stake if the trial doesn't go as planned.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.